This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IFF Announces CEO Succession Plan

IFF Inc. (NYSE:IFF), a leading global creator of flavors and fragrances used in an array of consumer products, today announced that Doug Tough will be stepping down as Chief Executive Officer, effective September 1, 2014. The Company’s Board of Directors has selected Andreas Fibig, a member of IFF’s Board of Directors since 2011, to succeed Mr. Tough as of that date. Mr. Tough, 64, will continue to serve as Chairman of IFF’s Board of Directors after September 1 st for a period to be determined. At such time, Mr. Fibig will assume the additional role of Chairman of the Board.

Mr. Fibig, 52, is a highly accomplished global business leader with significant experience overseeing an international business portfolio and expertise in emerging markets. Since 2008, he has served as President and Chairman of the Board of Management of Bayer HealthCare Pharmaceuticals, the pharmaceutical division of Bayer AG, where he has driven meaningful organic growth and its successful acquisition strategy. Prior to joining Bayer, Mr. Fibig held a number of positions of increasing responsibility at Pfizer Inc., including as Senior Vice President in the US Pharmaceutical Operations group and as President, Latin America, Africa and Middle East. He also held positions with Pharmacia GmbH and Boehringer Ingelheim GmbH.

Mr. Tough commented, “The Board and I are delighted that Andreas will become IFF’s next CEO. He brings the right combination of experience and skills to lead IFF’s continued growth and build on our success in leveraging our geographic reach, strengthening our innovation platform and maximizing our business portfolio. He has led businesses with an international footprint similar to ours, has firsthand experience in key emerging markets where we see further opportunity, and understands the critical importance of science-based research in driving innovation and competitiveness. In addition, we have valued his insightful contributions as a Board member over the past three years, particularly with respect to matters of international business, product development and strategic planning. I look forward to working closely with Andreas in the coming months on a smooth, seamless leadership transition.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs